Reata: A lean machine

Biotech companies developing therapies for cancer and inflammation are a dime a dozen, but Reata Pharmaceuticals Inc. believes that its outsourcing business model will allow it to develop a large portfolio on a modest budget.

The company also hopes to mitigate risk by developing treatments with both familiar and new disease-ameliorating mechanisms.

In 2002,

Read the full 527 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE